| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-0463.2005.APM_04.X |
| P698 | PubMed publication ID | 15865607 |
| P2093 | author name string | Nam Jin Yoo | |
| Sug Hyung Lee | |||
| Jung Young Lee | |||
| Su Young Kim | |||
| Suk Woo Nam | |||
| Won Sang Park | |||
| Ji Heon Noh | |||
| Jung Woo Eun | |||
| Jong Heun Lee | |||
| Young Min Ahn | |||
| Jaehwi Song | |||
| P2860 | cites work | A genetic model for colorectal tumorigenesis | Q27860582 |
| Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase | Q27860668 | ||
| Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins | Q28139564 | ||
| Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells | Q28142463 | ||
| Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family | Q28252866 | ||
| Gastric adenocarcinoma: pathomorphology and molecular pathology | Q34226916 | ||
| The impact of chromatin in human cancer: linking DNA methylation to gene silencing | Q34739107 | ||
| Histone deacetylase inhibitors: understanding a new wave of anticancer agents | Q35880073 | ||
| Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 | Q36017473 | ||
| Gastric carcinoma | Q40542262 | ||
| Inactivating mutations of the caspase-10 gene in gastric cancer | Q40735828 | ||
| Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis | Q44897188 | ||
| Life (and death) in a malignant tumour | Q59098941 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 264-268 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Acta Pathologica et Microbiologica Scandinavica | Q15756643 |
| P1476 | title | Increased expression of histone deacetylase 2 is found in human gastric cancer. | |
| P478 | volume | 113 |
| Q37716435 | A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis |
| Q39132750 | A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress. |
| Q34088141 | Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins |
| Q37141408 | Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy |
| Q29616624 | Anticancer activities of histone deacetylase inhibitors |
| Q52939500 | Assessment of Tissue Level of Histone Deactylase-2 (HDAC-2) in Patients With Mycosis Fungoides. |
| Q52920858 | Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. |
| Q30248745 | Biomarkers of genome instability and cancer epigenetics. |
| Q28972517 | Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor |
| Q39171071 | Cancer metastasis - tricks of the trade |
| Q64921703 | Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. |
| Q37073231 | Chromatin, cancer and drug therapies |
| Q42276089 | Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. |
| Q37483918 | Concordance between somatic copy number loss and down-regulated expression: A pan-cancer study of cancer predisposition genes. |
| Q89993835 | Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma |
| Q34408058 | Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells |
| Q38012499 | Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. |
| Q39011776 | Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. |
| Q37242496 | Discovery and mechanism of natural products as modulators of histone acetylation |
| Q93108193 | Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers |
| Q34989248 | Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties |
| Q95728272 | Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line |
| Q34583094 | Effects and mechanisms of silibinin on human hepatoma cell lines |
| Q34366588 | Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line |
| Q57570317 | Epigenetic Mechanisms in Cancer Formation and Progression |
| Q93082245 | Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy |
| Q33802356 | Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy |
| Q37830385 | Epigenetic aberrations during oncogenesis. |
| Q24625376 | Epigenetic alterations in aging |
| Q38058972 | Epigenetic alterations involved in cancer stem cell reprogramming |
| Q38204377 | Epigenetic biomarkers: potential applications in gastrointestinal cancers |
| Q34457187 | Epigenetic linkage of aging, cancer and nutrition |
| Q38018086 | Epigenetic mechanisms in gastric cancer |
| Q45938052 | Epigenetic mechanisms regulate placental c-myc and hTERT in normal and pathological pregnancies; c-myc as a novel fetal DNA epigenetic marker for pre-eclampsia. |
| Q28070086 | Epigenetic roles in the malignant transformation of gastric mucosal cells |
| Q36299715 | Epigenetically downregulated Semaphorin 3E contributes to gastric cancer |
| Q29617139 | Epigenetics in cancer |
| Q26749113 | Epigenetics in non-small cell lung cancer: from basics to therapeutics |
| Q28550025 | Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays |
| Q36343613 | Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas |
| Q34059184 | Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study |
| Q37442676 | Gastric cancer in the era of molecularly targeted agents: current drug development strategies |
| Q52721971 | Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases. |
| Q34734168 | Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation |
| Q35544903 | Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health? |
| Q26766640 | HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases |
| Q37073624 | HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses |
| Q36094073 | HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. |
| Q36487324 | HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers |
| Q39366437 | HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins |
| Q93119942 | HDAC2-dependent miRNA signature in acute myeloid leukemia |
| Q48880601 | Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. |
| Q41040835 | Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β-Catenin Target Genes |
| Q38696932 | Histone Deacetylase Inhibitors as Anticancer Drugs |
| Q37797706 | Histone Modification Therapy of Cancer |
| Q37970955 | Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis |
| Q35402636 | Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer |
| Q38344675 | Histone deacetylase inhibitors in hematological malignancies and solid tumors |
| Q37662700 | Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials |
| Q36019774 | Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. |
| Q34171631 | Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. |
| Q38335802 | Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer |
| Q28240447 | Histone deacetylases and cancer |
| Q37416288 | Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer |
| Q36206499 | Histone modifications and cancer: biomarkers of prognosis? |
| Q34109472 | Histones: Controlling Tumor Signaling Circuitry |
| Q48094915 | Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. |
| Q92882449 | Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer |
| Q50091965 | Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. |
| Q92441031 | In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity |
| Q33755131 | Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression |
| Q39691186 | Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer |
| Q28488474 | Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer |
| Q39808264 | Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors |
| Q38060735 | Interactions between epigenetics and metabolism in cancers |
| Q36611841 | Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues |
| Q36995048 | Isoform-selective histone deacetylase inhibitors |
| Q37667033 | Largazole pharmacokinetics in rats by LC-MS/MS. |
| Q89433601 | Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer |
| Q37588893 | Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. |
| Q39372689 | MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors |
| Q24629065 | Macrocyclic histone deacetylase inhibitors |
| Q48246333 | MicroRNA-31 Function as a Suppressor Was Regulated by Epigenetic Mechanisms in Gastric Cancer. |
| Q34063722 | Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties |
| Q35691776 | Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells |
| Q48533275 | Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells |
| Q24644030 | Monitoring the effect of belinostat in solid tumors by H4 acetylation |
| Q37979639 | Multiple roles of class I HDACs in proliferation, differentiation, and development |
| Q99237825 | Natural Products Impacting DNA Methyltransferases and Histone Deacetylases |
| Q27022413 | New and emerging HDAC inhibitors for cancer treatment |
| Q80601767 | Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray |
| Q36822431 | Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy |
| Q55007506 | Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. |
| Q49685824 | Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs |
| Q52757724 | Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer. |
| Q39955238 | Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma |
| Q37226511 | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| Q38340102 | Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. |
| Q36862120 | Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis |
| Q34413200 | Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors |
| Q34258037 | Targeting DNA methylation for epigenetic therapy |
| Q35821728 | Targeting Histone Deacetylases in Diseases: Where Are We? |
| Q53201323 | Targeting the epigenome for treatment of cancer. |
| Q47927498 | Targeting triple negative breast cancer with histone deacetylase inhibitors |
| Q38016153 | The epigenetics of renal cell tumors: from biology to biomarkers. |
| Q39583323 | The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells |
| Q38979892 | The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair |
| Q61797524 | The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer |
| Q37453782 | The role of histone deacetylases (HDACs) in human cancer |
| Q37333510 | The role of histone deacetylases in prostate cancer. |
| Q37346960 | The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity |
| Q37098965 | The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position |
| Q35133494 | The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. |
| Q38782882 | Transcript level of AKR1C3 is down-regulated in gastric cancer |
| Q39394558 | Translating cancer epigenomics into the clinic: focus on lung cancer |
| Q34363130 | Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. |
| Q51374040 | Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. |
| Q35939690 | Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects |
Search more.